{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:30:12Z","timestamp":1740180612831,"version":"3.37.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T00:00:00Z","timestamp":1597536000000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The whole world is confronting the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unfortunately, there is no vaccine to prevent novel coronavirus infection. Besides several experimental drugs, the strong immune responses and convalescent sera are the current two potential options to tackle coronavirus disease 2019 (COVID-19) infection. Innate immune-mediated antiviral responses are initiated by the recognition of viral invasion through pathogen-associated molecular patterns (PAMPs). In coronavirus, the PAMPs are recognized by Toll-like receptors 3 and 7, endosomal ribonucleic acid receptors, RNA in cytosol, and by pattern recognition receptor (RIG-1) in the alveolar cells and site of invasion. Nuclear factor-\u03baB and interferon regulatory transcription factor (IRF3) are activated in response to the above recognition episode and translocate to nucleus. These transcription factors in the nucleus initiate the expression of interferon type 1 and pro-inflammatory cytokine storm, which leads to first line of defense at the site of viral entrance. The effectiveness of innate immune system is greatly relies on type 1 interferons and its cascade, because of their role in the inhibition of viral replication and initiation of adaptive immune responses. The successful interferon type 1 response put down the viral replication and transmission at prompt point. Passive immunization is the administering of antibodies into infected patients, which is taken from recovered individuals. The convalescent sera of the recovered COVID-19 patients are containing antiviral neutralizing antibodies and are used therapeutically for infected individuals by SARS-CoV-2 and for the purpose of prophylaxis in exposed individuals. The convalescent sera is found effective when administered early at the onset of symptoms.<\/jats:p>","DOI":"10.1093\/abt\/tbaa019","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T12:16:49Z","timestamp":1597580209000},"page":"212-220","source":"Crossref","is-referenced-by-count":2,"title":["Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-5045","authenticated-orcid":false,"family":"Abdullah","sequence":"first","affiliation":[{"name":"Department of Microbiology, Abdul Wali Khan University, Mardan, 23000, KPK, Pakistan"},{"name":"Department of Life Sciences, Abasyn University, Peshawar, 25000, KPK, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shah","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Bacha Khan University, Charsadda, 24420, KPK, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Aman","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Abasyn University, Peshawar, 25000, KPK, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anees ur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Abasyn University, Peshawar, 25000, KPK, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,16]]},"reference":[{"key":"2020121009341030600_ref1","doi-asserted-by":"crossref","DOI":"10.17987\/icfj.v20i0.695","volume-title":"A perspective study on oral-fecal transmission of COVID-19, its prevention and management","author":"Abdullah","year":"2020"},{"author":"Worldometers","key":"2020121009341030600_ref2"},{"key":"2020121009341030600_ref3","doi-asserted-by":"crossref","DOI":"10.38125\/OAJBS.000168","article-title":"The pandemic of novel coronavirus disease 2019 (COVID-19): need for an immediate action","author":"Ullah","year":"2020"},{"issue":"3","key":"2020121009341030600_ref4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"2020121009341030600_ref5","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2020121009341030600_ref6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"volume-title":"Symptoms of novel coronavirus (2019-nCoV) [about 1 screen]","author":"Center for Disease Control and Prevention","key":"2020121009341030600_ref7"},{"key":"2020121009341030600_ref8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"2020121009341030600_ref9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2020121009341030600_ref10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(09)70069-6","article-title":"Incubation periods of acute respiratory viral infections: a systematic review","volume":"9","author":"Lessler","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2020121009341030600_ref11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088716","article-title":"Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?","volume":"9","author":"Faure","year":"2014","journal-title":"PLoS One"},{"key":"2020121009341030600_ref12","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/jcp.27155","article-title":"Modulation of the immune response by Middle East respiratory syndrome coronavirus","volume":"234","author":"Shokri","year":"2019","journal-title":"J Cell Physiol"},{"issue":"4","key":"2020121009341030600_ref13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"2020121009341030600_ref14","first-page":"15","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2020121009341030600_ref15","first-page":"19","article-title":"A new coronavirus associated with human respiratory disease in China","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"2020121009341030600_ref16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"2020121009341030600_ref17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"2020121009341030600_ref18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2020121009341030600_ref19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"2020121009341030600_ref20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","article-title":"A serological survey on neutralizing antibody titer of SARS convalescent sera","volume":"77","author":"Zhang","year":"2005","journal-title":"J Med Virol"},{"issue":"4","key":"2020121009341030600_ref21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","article-title":"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study","volume":"18","author":"Beigel","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2020121009341030600_ref22","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/171.6.1387","article-title":"Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum","volume":"171","author":"Robbins","year":"1995","journal-title":"J Infect Dis"},{"issue":"9","key":"2020121009341030600_ref23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","article-title":"Antibody-mediated regulation of cellular immunity and the inflammatory response","volume":"24","author":"Casadevall","year":"2003","journal-title":"Trends Immunol"},{"issue":"8","key":"2020121009341030600_ref24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"Serum therapy revisted: animal models of infection and development of passive antibody therapy","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2020121009341030600_ref25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jama.1926.02680080022009","article-title":"The prophylactic use of measles convalescent serum","volume":"87","author":"Park","year":"1926","journal-title":"JAMA"},{"issue":"5","key":"2020121009341030600_ref26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2105\/AJPH.25.5.595","article-title":"Use of convalescent measles serum to control measles in a preparatory school","volume":"25","author":"Gallagher","year":"1935","journal-title":"Am J Public Health Nations Health"},{"key":"2020121009341030600_ref27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.1932.02740650008003","article-title":"Therapeutic use of antipoliomyelitits serum in preparalytic cases of poliomyelitis","volume":"99","author":"Park","year":"1932","journal-title":"JAMA"},{"issue":"4 suppl","key":"2020121009341030600_ref28","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/CCM.0b013e3181d44c1e","article-title":"Hark back: passive immunotherapy for influenza and other serious infections","volume":"38","author":"Luke","year":"2010","journal-title":"Crit Care Med"},{"key":"2020121009341030600_ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archpedi.1946.02020240008001","article-title":"Mumps; use of convalescent serum in the treatment and prophylaxis of orchitis","volume":"71","author":"Rambar","year":"1946","journal-title":"Am J Dis Child"},{"issue":"8","key":"2020121009341030600_ref30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020121009341030600_ref31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza a (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020121009341030600_ref32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","article-title":"Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone","volume":"74","author":"Sahr","year":"2017","journal-title":"J Infect"},{"issue":"4","key":"2020121009341030600_ref33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States","volume":"61","author":"Kraft","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2020121009341030600_ref34","first-page":"489","article-title":"Successful treatment of avian influenza with convalescent plasma","volume":"12","author":"Kong","year":"2006","journal-title":"Hong Kong Med J"},{"issue":"14","key":"2020121009341030600_ref35","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza a (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"key":"2020121009341030600_ref36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","article-title":"Successful treatment of avian-origin influenza a (H7N9) infection using convalescent plasma","volume":"41","author":"Wu","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2020121009341030600_ref37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2020121009341030600_ref38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2020121009341030600_ref39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single Centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther (Lond)"},{"issue":"9","key":"2020121009341030600_ref40","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerging Infect Dis"},{"key":"2020121009341030600_ref41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"Erp","year":"2019","journal-title":"Front Immunol"},{"key":"2020121009341030600_ref42","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3389\/fimmu.2019.02110","article-title":"The roles of host and viral antibody fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity","volume":"10","author":"Jenks","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"2020121009341030600_ref43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A role for fc function in therapeutic monoclonal antibody-mediated protection against ebola virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"volume-title":"China puts 245 COVID-19 patients on convalescent plasma therapy","year":"28 2020","key":"2020121009341030600_ref44"},{"issue":"5","key":"2020121009341030600_ref45","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"issue":"1","key":"2020121009341030600_ref46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"7","key":"2020121009341030600_ref47","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.4049\/jimmunol.167.7.3910","article-title":"Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines","volume":"167","author":"Crowe","year":"2001","journal-title":"J Immunol"},{"issue":"2","key":"2020121009341030600_ref48","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.15190\/d.2020","article-title":"COVID-19: review of epidemiology and potential treatments against 2019 novel coronavirus","volume":"8","author":"Jan","year":"2020","journal-title":"Discoveries"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbaa019\/33654760\/tbaa019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/abt\/article-pdf\/3\/3\/212\/34842564\/tbaa019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/abt\/article-pdf\/3\/3\/212\/34842564\/tbaa019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T08:12:23Z","timestamp":1667808743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/3\/3\/212\/5893021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbaa019","relation":{},"ISSN":["2516-4236"],"issn-type":[{"type":"electronic","value":"2516-4236"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,7]]}}}